JP2012140442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012140442A5 JP2012140442A5 JP2012036919A JP2012036919A JP2012140442A5 JP 2012140442 A5 JP2012140442 A5 JP 2012140442A5 JP 2012036919 A JP2012036919 A JP 2012036919A JP 2012036919 A JP2012036919 A JP 2012036919A JP 2012140442 A5 JP2012140442 A5 JP 2012140442A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- pathway
- dna
- treated
- initial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55357804P | 2004-03-15 | 2004-03-15 | |
US60/553,578 | 2004-03-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503972A Division JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014091125A Division JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012140442A JP2012140442A (ja) | 2012-07-26 |
JP2012140442A5 true JP2012140442A5 (es) | 2013-04-04 |
Family
ID=34993432
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Sns−595、及びその使用方法 |
JP2012036919A Pending JP2012140442A (ja) | 2004-03-15 | 2012-02-23 | Sns−595、及びその使用方法 |
JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Sns−595、及びその使用方法 |
JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Sns−595、及びその使用方法 |
JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Sns−595、及びその使用方法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007503987A Expired - Fee Related JP5317472B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2007503972A Expired - Fee Related JP5096913B2 (ja) | 2004-03-15 | 2005-03-14 | Sns−595、及びその使用方法 |
JP2011135675A Pending JP2011225590A (ja) | 2004-03-15 | 2011-06-17 | Sns−595、及びその使用方法 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014091125A Expired - Fee Related JP5856644B2 (ja) | 2004-03-15 | 2014-04-25 | Sns−595、及びその使用方法 |
JP2014180862A Expired - Fee Related JP6261477B2 (ja) | 2004-03-15 | 2014-09-05 | Sns−595、及びその使用方法 |
JP2015140309A Expired - Fee Related JP6352863B2 (ja) | 2004-03-15 | 2015-07-14 | Sns−595、及びその使用方法 |
JP2016248041A Pending JP2017095471A (ja) | 2004-03-15 | 2016-12-21 | Sns−595、及びその使用方法 |
JP2018038834A Pending JP2018119977A (ja) | 2004-03-15 | 2018-03-05 | Sns−595、及びその使用方法 |
Country Status (24)
Country | Link |
---|---|
US (12) | US7989468B2 (es) |
EP (4) | EP2295056B9 (es) |
JP (9) | JP5317472B2 (es) |
KR (1) | KR101169825B1 (es) |
CN (5) | CN104324029A (es) |
AT (2) | ATE493982T1 (es) |
AU (3) | AU2005222622B2 (es) |
BR (1) | BRPI0508700A (es) |
CA (3) | CA2559652C (es) |
CY (2) | CY1109741T1 (es) |
DE (2) | DE602005018333D1 (es) |
DK (3) | DK2295056T5 (es) |
ES (3) | ES2334802T3 (es) |
HK (1) | HK1097196A1 (es) |
HU (1) | HUE027266T2 (es) |
IL (2) | IL177946A (es) |
MX (2) | MXPA06010382A (es) |
NO (3) | NO338058B1 (es) |
NZ (2) | NZ549557A (es) |
PL (3) | PL1729770T3 (es) |
PT (2) | PT1725233E (es) |
SI (2) | SI1729770T1 (es) |
WO (2) | WO2005089757A1 (es) |
ZA (1) | ZA200607248B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2559652C (en) | 2004-03-15 | 2017-02-14 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 in treating cancer |
BRPI0515319A (pt) | 2004-09-17 | 2008-07-22 | Cylene Pharmaceuticals Inc | análogos de quinolona |
US7652134B2 (en) | 2004-09-17 | 2010-01-26 | Cylene Pharmaceuticals, Inc. | Methods for converting quinolone esters into quinolone amides |
US20070117770A1 (en) * | 2005-08-19 | 2007-05-24 | Cylene Pharmaceuticals, Inc. | Human ribosomal DNA (rDNA) and ribosomal RNA (rRNA) nucleic acids and uses thereof |
US8580814B2 (en) * | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
EP1931339B1 (en) * | 2005-09-02 | 2018-05-16 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
CA2845095A1 (en) * | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
BRPI0713637A2 (pt) * | 2006-06-12 | 2012-10-23 | Sunesis Pharmaceuticals Inc | composição, composto, e , método para o tratamento de cáncer |
WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
US20080063642A1 (en) | 2006-08-02 | 2008-03-13 | Adelman Daniel C | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
WO2009049030A1 (en) * | 2007-10-09 | 2009-04-16 | Triton Biopharma, Llc | Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter |
AU2014277779B2 (en) * | 2007-10-22 | 2016-05-19 | Sunesis Pharmaceuticals, Inc. | METHODS OF USING (+)-1,4-DIHYDRO-7-[(3s,4s)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID IN COMBINATION THERAPY |
EP3141250A1 (en) * | 2007-10-22 | 2017-03-15 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
EP2649997B1 (en) * | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
MX2011006974A (es) * | 2008-12-31 | 2011-11-18 | Sunesis Pharmaceuticals Inc | Metodo para preparar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-( metilamino)-1-pirrolidinil]-4-oxo-1-) (2-tiazolil)-1, 8-naftiridin-3-carboxilico. |
SG173855A1 (en) | 2009-02-27 | 2011-09-29 | Sunesis Pharmaceuticals Inc | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
UA110465C2 (en) * | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
TW201120037A (en) * | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
PE20150100A1 (es) | 2012-02-27 | 2015-01-24 | Agq Technological Corporate S A | Monitoreo y control de las condiciones del suelo |
NZ700928A (en) | 2012-04-24 | 2017-06-30 | Vertex Pharma | Dna-pk inhibitors |
KR102216284B1 (ko) | 2013-03-12 | 2021-02-18 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-pk 억제제 |
US20160067182A1 (en) * | 2013-04-09 | 2016-03-10 | Merrimack Pharmaceuticals, Inc. | Methods and compositions for improving outcomes of liposomal chemotherapy |
EP3016659A4 (en) * | 2013-07-02 | 2017-03-15 | Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) | Method for preventing and/or treating chronic traumatic encephalopathy-iii |
HUE041877T2 (hu) | 2013-10-17 | 2019-06-28 | Vertex Pharma | (S)-N-Metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propán-2-il)kinolin-4-karboxamid kokristályai és deuterált származékai DNS-PK inhibitorokként |
KR101775356B1 (ko) * | 2015-07-06 | 2017-09-06 | 재단법인 아산사회복지재단 | Parp 및 탄키라제 동시 저해제에 대한 감수성 결정 방법 |
RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US216316A (en) * | 1879-06-10 | Improvement in latches | ||
US3021A (en) * | 1843-03-30 | Stove with elevated ovejst | ||
US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
US5078996A (en) * | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
SI0787726T1 (en) * | 1994-06-14 | 2002-04-30 | Dainippon Pharmaceutical Co., Ltd. | Novel compound, process for producing the same, and antitumor agent |
JP4323574B2 (ja) | 1995-12-13 | 2009-09-02 | 大日本住友製薬株式会社 | 抗腫瘍剤 |
US6753158B1 (en) * | 1997-01-13 | 2004-06-22 | Kudos Pharmaceuticals Limited | Assays, agents, therapy and diagnosis relating to modulation of cellular DNA repair activity |
US20020032216A1 (en) * | 1997-03-21 | 2002-03-14 | Lg Chemical Ltd. | Salt of naphthyridine carboxylic acid derivative |
CA2293724C (en) * | 1997-06-05 | 2010-02-02 | Xiaodong Wang | Apaf-1, the ced-4 human homolog, an activator of caspase-3 |
US6171857B1 (en) * | 1997-10-17 | 2001-01-09 | Brown University Research Foundatiion | Leucine zipper protein, KARP-1 and methods of regulating DNA dependent protein kinase activity |
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
IL124015A0 (en) * | 1998-04-08 | 1999-01-26 | Yeda Res & Dev | Pharmaceutical compositions comprising a protein |
JP4294121B2 (ja) | 1998-06-05 | 2009-07-08 | 大日本住友製薬株式会社 | ピリドンカルボン酸誘導体の製造方法およびその中間体 |
EP1090146B1 (en) * | 1998-06-30 | 2007-05-23 | Sloan-Kettering Institute For Cancer Research | Uses of dna-pk |
US6670144B1 (en) | 1999-02-26 | 2003-12-30 | Cyclacel, Ltd. | Compositions and methods for monitoring the phosphorylation of natural binding partners |
AU760466B2 (en) * | 1999-02-26 | 2003-05-15 | Johns Hopkins University, The | A novel inhibitor of programmed cell death |
US7163801B2 (en) | 1999-09-01 | 2007-01-16 | The Burnham Institute | Methods for determining the prognosis for cancer patients using tucan |
US6479541B1 (en) * | 2000-03-30 | 2002-11-12 | Baxter International | Amiodarone-containing parenteral administration |
AU2001256530A1 (en) * | 2000-05-20 | 2001-12-03 | Cancer Research Technology Limited | Drug screening systems and assays |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
WO2002028387A1 (en) * | 2000-10-03 | 2002-04-11 | Oncopharmaceutical, Inc. | Inhibitors of angiogenesis and tumor growth for local and systemic administration |
AU2877202A (en) * | 2000-11-02 | 2002-05-15 | Sloan Kettering Inst Cancer | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
WO2003089573A2 (en) * | 2002-04-05 | 2003-10-30 | Fishel Richard A | Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
US8404681B2 (en) | 2003-03-24 | 2013-03-26 | Luitpold Pharmaceuticals, Inc. | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors |
CA2559652C (en) * | 2004-03-15 | 2017-02-14 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 in treating cancer |
US8580814B2 (en) | 2006-04-03 | 2013-11-12 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
EP1931339B1 (en) | 2005-09-02 | 2018-05-16 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
BRPI0713637A2 (pt) * | 2006-06-12 | 2012-10-23 | Sunesis Pharmaceuticals Inc | composição, composto, e , método para o tratamento de cáncer |
WO2008016678A2 (en) | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
US20080063642A1 (en) * | 2006-08-02 | 2008-03-13 | Adelman Daniel C | Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders |
EP3141250A1 (en) | 2007-10-22 | 2017-03-15 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy |
EP2649997B1 (en) | 2007-12-10 | 2019-01-23 | Sunesis Pharmaceuticals, Inc. | (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for use in the treatment of myelodyspastic syndrome |
MX2011006974A (es) | 2008-12-31 | 2011-11-18 | Sunesis Pharmaceuticals Inc | Metodo para preparar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-( metilamino)-1-pirrolidinil]-4-oxo-1-) (2-tiazolil)-1, 8-naftiridin-3-carboxilico. |
SG173855A1 (en) | 2009-02-27 | 2011-09-29 | Sunesis Pharmaceuticals Inc | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
CN101631081B (zh) | 2009-08-12 | 2011-06-08 | 华为技术有限公司 | 一种多级交换网 |
UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
TW201120037A (en) | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
-
2005
- 2005-03-14 CA CA2559652A patent/CA2559652C/en not_active Expired - Fee Related
- 2005-03-14 NZ NZ549557A patent/NZ549557A/en not_active IP Right Cessation
- 2005-03-14 CN CN201410477839.4A patent/CN104324029A/zh active Pending
- 2005-03-14 EP EP10177951.0A patent/EP2295056B9/en not_active Not-in-force
- 2005-03-14 ZA ZA200607248A patent/ZA200607248B/xx unknown
- 2005-03-14 US US11/080,283 patent/US7989468B2/en not_active Expired - Fee Related
- 2005-03-14 DE DE602005018333T patent/DE602005018333D1/de active Active
- 2005-03-14 AT AT05731600T patent/ATE493982T1/de active
- 2005-03-14 WO PCT/US2005/008346 patent/WO2005089757A1/en active Application Filing
- 2005-03-14 DK DK10177951.0T patent/DK2295056T5/en active
- 2005-03-14 PL PL05732554T patent/PL1729770T3/pl unknown
- 2005-03-14 ES ES05732554T patent/ES2334802T3/es active Active
- 2005-03-14 PT PT05731600T patent/PT1725233E/pt unknown
- 2005-03-14 MX MXPA06010382A patent/MXPA06010382A/es active IP Right Grant
- 2005-03-14 ES ES05731600T patent/ES2358267T3/es active Active
- 2005-03-14 EP EP05731600A patent/EP1725233B1/en not_active Not-in-force
- 2005-03-14 DK DK05732554.0T patent/DK1729770T3/da active
- 2005-03-14 HU HUE10177951A patent/HUE027266T2/en unknown
- 2005-03-14 SI SI200530890T patent/SI1729770T1/sl unknown
- 2005-03-14 EP EP15202939.3A patent/EP3053579A1/en not_active Withdrawn
- 2005-03-14 JP JP2007503987A patent/JP5317472B2/ja not_active Expired - Fee Related
- 2005-03-14 EP EP05732554A patent/EP1729770B1/en not_active Not-in-force
- 2005-03-14 WO PCT/US2005/008036 patent/WO2005089756A1/en active Application Filing
- 2005-03-14 MX MX2011011851A patent/MX349188B/es unknown
- 2005-03-14 BR BRPI0508700-7A patent/BRPI0508700A/pt not_active IP Right Cessation
- 2005-03-14 JP JP2007503972A patent/JP5096913B2/ja not_active Expired - Fee Related
- 2005-03-14 SI SI200531244T patent/SI1725233T1/sl unknown
- 2005-03-14 US US11/080,102 patent/US7968565B2/en not_active Expired - Fee Related
- 2005-03-14 ES ES10177951.0T patent/ES2566973T3/es active Active
- 2005-03-14 KR KR1020067021270A patent/KR101169825B1/ko active IP Right Grant
- 2005-03-14 CA CA2954578A patent/CA2954578A1/en not_active Abandoned
- 2005-03-14 CN CN200580015456.4A patent/CN1997368B/zh not_active Expired - Fee Related
- 2005-03-14 PL PL10177951T patent/PL2295056T3/pl unknown
- 2005-03-14 DE DE602005025738T patent/DE602005025738D1/de active Active
- 2005-03-14 PT PT05732554T patent/PT1729770E/pt unknown
- 2005-03-14 AT AT05732554T patent/ATE451924T1/de active
- 2005-03-14 AU AU2005222622A patent/AU2005222622B2/en not_active Ceased
- 2005-03-14 PL PL05731600T patent/PL1725233T3/pl unknown
- 2005-03-14 AU AU2005222607A patent/AU2005222607B2/en not_active Ceased
- 2005-03-14 CN CN201210307920.9A patent/CN103083316B/zh not_active Expired - Fee Related
- 2005-03-14 CA CA2559650A patent/CA2559650C/en not_active Expired - Fee Related
- 2005-03-14 CN CN201210307785.8A patent/CN103251589B/zh not_active Expired - Fee Related
- 2005-03-14 DK DK05731600.2T patent/DK1725233T3/da active
- 2005-03-14 CN CN200910221540A patent/CN101703508A/zh active Pending
- 2005-04-14 NZ NZ588060A patent/NZ588060A/en not_active IP Right Cessation
- 2005-09-02 US US11/218,653 patent/US20060063795A1/en active Pending
- 2005-09-02 US US11/218,387 patent/US20060025437A1/en active Pending
-
2006
- 2006-06-29 US US11/478,765 patent/US7829577B2/en not_active Expired - Fee Related
- 2006-09-07 IL IL177946A patent/IL177946A/en not_active IP Right Cessation
- 2006-10-12 NO NO20064647A patent/NO338058B1/no not_active IP Right Cessation
-
2007
- 2007-05-07 HK HK07104836.3A patent/HK1097196A1/xx not_active IP Right Cessation
-
2010
- 2010-01-21 CY CY20101100063T patent/CY1109741T1/el unknown
-
2011
- 2011-02-03 CY CY20111100114T patent/CY1111263T1/el unknown
- 2011-03-22 AU AU2011201277A patent/AU2011201277B2/en not_active Ceased
- 2011-04-27 US US13/095,111 patent/US20110263524A1/en not_active Abandoned
- 2011-06-13 US US13/159,258 patent/US8669270B2/en not_active Expired - Fee Related
- 2011-06-17 JP JP2011135675A patent/JP2011225590A/ja active Pending
-
2012
- 2012-02-23 JP JP2012036919A patent/JP2012140442A/ja active Pending
-
2013
- 2013-03-11 US US13/794,583 patent/US8822493B2/en not_active Expired - Fee Related
-
2014
- 2014-02-03 US US14/171,673 patent/US20140378505A1/en not_active Abandoned
- 2014-04-25 JP JP2014091125A patent/JP5856644B2/ja not_active Expired - Fee Related
- 2014-08-18 US US14/462,439 patent/US9980949B2/en not_active Expired - Fee Related
- 2014-09-05 JP JP2014180862A patent/JP6261477B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-17 NO NO20150466A patent/NO339613B1/no not_active IP Right Cessation
- 2015-07-14 JP JP2015140309A patent/JP6352863B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-14 US US14/996,025 patent/US9757363B2/en not_active Expired - Fee Related
- 2016-09-26 IL IL248049A patent/IL248049A0/en unknown
- 2016-11-24 NO NO20161867A patent/NO20161867A1/no not_active Application Discontinuation
- 2016-12-21 JP JP2016248041A patent/JP2017095471A/ja active Pending
-
2018
- 2018-03-05 JP JP2018038834A patent/JP2018119977A/ja active Pending
- 2018-04-27 US US15/965,741 patent/US20180316309A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012140442A5 (es) | ||
EP3082840A4 (en) | Methods and assays relating to circulating tumor cells | |
EP2850675A4 (en) | ELECTROCHEMICAL CELLS AND METHODS OF MAKING THE SAME | |
WO2013006490A3 (en) | Antibodies that specifically bind to tim3 | |
EP2853597A4 (en) | NUCLEIC ACID MOLECULE INDUCING INTERFERING RNA CAPABLE OF PENETRATING IN CELLS AND USE THEREOF | |
CL2015000084A1 (es) | Célula huésped, particularmente de hongo filamentoso, deficiente en la producción de proteína agse; y método de producción de la célula. | |
EP2827842A4 (en) | CYCLODEXTRIN MICROEMULSIONS AND DERMATOLOGICAL USES THEREOF | |
BR112014005355A2 (pt) | células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença | |
CL2013000238A1 (es) | Uso de inhibores de la succinato deshidrogenasa y/o inhibidores del complejo iii para mejorar la relacion entre microorganismos dañinos y beneficiosos. | |
EP2976316A4 (en) | PERYLENEMONOIMIDE AND NAPHTHALENEMONOIMIDE DERIVATIVES AND THEIR USE IN DYE SENSITIZED PHOTOPILES | |
JP2012144538A5 (es) | ||
EP3063267A4 (en) | Cardiac neural crest cells and methods of use thereof | |
HK1214624A1 (zh) | 心臟幹細胞和其識別方法和用途 | |
HK1205185A1 (en) | Methods and composition related to brown adipose-like cells | |
EP3009502A4 (en) | Cell culture equipment coated with laminin fragments in dry state | |
TR201911039T4 (tr) | Ptp1b ile ilişkili bir hastalığın tedavisine yönelik aminosteroidler. | |
EP2807209A4 (de) | Kompositmaterial, dessen herstellung und dessen verwendung in separatoren für elektrochemische zellen | |
WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
HUE038546T2 (hu) | Száraz helyiség, különösen lítium-ion cellagyártásnál történõ alkalmazásra | |
EP3094956A4 (en) | Preparation of cells, cell aggregates, and tissue fragments | |
DK2920282T3 (da) | Alkylenkoblede phenoler til anvendelse i biodieselmotorer | |
IL232642A0 (en) | A method for characterizing circulating cells and its use in diagnosis | |
PT2859092T (pt) | ¿vacina terapêutica para tratamento de diabetes tipo 1 em crianças, aplicação do separador de células e método de multiplicação de células treg para produzir a vacina terapêutica para tratamento de diabetes tipo 1¿ | |
CO6801702A2 (es) | El uso de la vinaza en el proceso de sacrificación de la biomasa lignocelulósica | |
WO2012068038A3 (en) | Caffeic acid derivatives and their use in improving neuronal cell viability |